[Form 4/A] AdaptHealth Corp. Amended Insider Trading Activity

AdaptHealth Corp. insiders reported open-market purchases of common stock by entities affiliated with One Equity Partners.

Rhea-AI Filing Summary

AdaptHealth Corp. insiders reported open-market purchases of common stock by entities affiliated with One Equity Partners. OEP AHCO Investment Holdings, LLC bought 447,100 shares on March 20, 2026 at a weighted average price of $9.9121 per share and 727 shares on March 19, 2026 at a weighted average price of $9.9417 per share.

After these trades, the filing shows 16,312,698 shares of AdaptHealth common stock held indirectly following the latest transaction. The securities are held directly by OEP AHCO Investment Holdings, LLC, which is owned by several parallel One Equity Partners funds. A six-member investment committee of OEP VII GP, including Richard Cashin, may be deemed to have voting and investment discretion, though each reporting person disclaims beneficial ownership beyond its or his pecuniary interest.

Insider Trade Summary

Net Buyer: 447,827 shares

Net Buy 2 txns

Insider OEP VII GP, L.L.C., OEP AHCO Investment Holdings, LLC, ONE EQUITY PARTNERS VII, L.P., ONE EQUITY PARTNERS VII-A, L.P., ONE EQUITY PARTNERS VII-B, L.P., OEP VII Project A Co-Investment Partners, L.P., OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P., OEP VII General Partner, L.P., CASHIN RICHARD M JR

Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner

Bought 447,827 shs ($4.44M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	447,100	$9.9121	$4.43M
Purchase	Common Stock	727	$9.9417	$7K

Holdings After Transaction: Common Stock — 16,312,698 shares (Indirect, See)

Footnotes (4)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").
3. F3. (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.
4. F4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares bought 2026-03-20: 447,100 shares Price 2026-03-20: $9.9121 per share Shares bought 2026-03-19: 727 shares +3 more

6 metrics

Shares bought 2026-03-20 447,100 shares Open-market purchase of AdaptHealth common stock at weighted average price

Price 2026-03-20 $9.9121 per share Weighted average purchase price for 447,100 shares

Shares bought 2026-03-19 727 shares Open-market purchase of AdaptHealth common stock at weighted average price

Price 2026-03-19 $9.9417 per share Weighted average purchase price for 727 shares

Net shares bought 447,827 shares Total net buy across reported transactions

Indirect holdings after trades 16,312,698 shares Total AdaptHealth common stock held indirectly following March 20, 2026 purchase

Key Terms

open-market purchase, weighted average price, beneficial ownership, pecuniary interest, +1 more

5 terms

open-market purchase financial

"transaction_action is described as an open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported is a weighted average price for multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"Each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest therein"

indirect ownership financial

"The securities are held directly by OEP AHCO Investment Holdings, LLC and reported as indirect ownership"

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 07:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OEP VII GP, L.L.C.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AdaptHealth Corp. [ AHCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		P		727	A	$9.9417(1)	15,865,598	I	See(2)(3)
Common Stock	03/20/2026		P		447,100	A	$9.9121(4)	16,312,698	I	See(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

OEP VII GP, L.L.C.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP AHCO Investment Holdings, LLC

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ONE EQUITY PARTNERS VII, L.P.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ONE EQUITY PARTNERS VII-A, L.P.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

ONE EQUITY PARTNERS VII-B, L.P.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP VII Project A Co-Investment Partners, L.P.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

OEP VII General Partner, L.P.

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

CASHIN RICHARD M JR

(Last) (First) (Middle)

C/O ONE EQUITY PARTNERS

510 MADISON AVENUE, 19TH FLOOR

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

3. (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

This filing is being amended solely to reflect Investor, the Parallel Funds, OEP VII GP, OEP VII GP LLC (collectively, the "OEP Entities") as reporting persons and direct and indirect holders of the reported securities, which were previously reported on a Form 4 that was timely filed by Richard Cashin on March 23, 2026 (the "Original Form 4 Filing"). As noted in the remarks, the Original Form 4 Filing disclosed the OEP Entities' direct and indirect ownership and noted that Edgar filing codes were not available at such time but that the Original Form 4 Filing would be amended once such codes became available.

	OEP VII GP, L.L.C., By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP AHCO INVESTMENT HOLDINGS, LLC, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	ONE EQUITY PARTNERS VII, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	ONE EQUITY PARTNERS VII-A, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	ONE EQUITY PARTNERS VII-B, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP VII PROJECT A CO-INVESTMENT PARTNERS, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P., By: OEP VII General Partner, L.P., its general partner, By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	OEP VII GENERAL PARTNER, L.P., By: OEP VII GP, L.L.C., its general partner, By: /s/ Gregory Belinfanti, Authorized Person	03/30/2026
	/s/ Richard Cashin	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)